Biogen Inc. and UCB SA have presented new Phase 3 analyses showing that investigational dapirolizumab pegol was associated with higher rates of sustained low disease activity and remission in systemic lupus erythematosus, adding clinical context to the previously positive PHOENYCS GO pivotal trial. Across Weeks 40, 44 and 48, 24.0% of patients receiving dapirolizumab pegol plus standard of care maintained Lupus Low Disease Activity State compared with 10.3% receiving placebo plus standard therapy.
The new ACR Convergence 2026 data strengthen the case that the drug’s original positive BICLA result was accompanied by improvements across several measures that matter in long-term lupus management. However, the remission, low-disease-activity and novel organ-domain analyses were post-hoc, and their reported p-values were nominal rather than part of the original confirmatory statistical hierarchy.
That distinction is particularly important because dapirolizumab pegol is not approaching an immediate regulatory decision. Biogen and UCB are running a second confirmatory Phase 3 trial, PHOENYCS FLY, involving approximately 450 participants, with topline results expected in 2028. The fresh data therefore improve confidence in the biological and clinical signal, but the next pivotal study remains the programme’s biggest de-risking event.
What did the original Phase 3 PHOENYCS GO trial establish for dapirolizumab pegol?
PHOENYCS GO was a randomised, double-blind, placebo-controlled Phase 3 trial involving 321 adults with moderately to severely active systemic lupus erythematosus. Participants received intravenous dapirolizumab pegol at 24 mg/kg every four weeks plus standard of care or placebo plus standard treatment for 48 weeks.
The primary endpoint was a British Isles Lupus Assessment Group-based Composite Lupus Assessment, or BICLA, response at Week 48. In the full analysis population, approximately 50% of patients receiving dapirolizumab pegol achieved a BICLA response compared with 35% receiving placebo, an absolute difference of 14.6 percentage points that was statistically significant.
BICLA is designed to capture improvement in active lupus disease while ensuring that patients do not experience meaningful worsening in other organ systems. That makes the endpoint useful in a disease where symptoms can affect the skin, joints, blood, kidneys and other organs simultaneously and where improvement in one domain can coexist with deterioration elsewhere.
The trial also showed a higher SRI-4 response rate with dapirolizumab pegol, at 60% compared with 41% for placebo. That secondary result was not controlled for multiplicity, meaning it supports the overall efficacy signal but does not carry the same confirmatory statistical status as the successfully met primary BICLA endpoint.
Why are the new sustained remission data clinically more interesting than another response percentage?
Systemic lupus erythematosus is a chronic relapsing disease, so achieving improvement at a single visit does not necessarily establish durable disease control. Clinicians increasingly focus on sustained low disease activity and remission because prolonged disease suppression, together with lower glucocorticoid exposure, is associated with better long-term outcomes and less accumulated organ damage.
In the fresh PHOENYCS GO analysis, 24.0% of patients receiving dapirolizumab pegol plus standard therapy achieved sustained Lupus Low Disease Activity State at all three final study visits, Weeks 40, 44 and 48. That compared with 10.3% receiving placebo plus standard of care.
When investigators applied a more restrictive definition requiring prednisone-equivalent glucocorticoid use of no more than 5 mg per day, 19.2% of dapirolizumab-treated participants achieved sustained LLDAS-5 compared with 5.6% receiving placebo. Sustained DORIS remission was achieved by 11.5% versus 4.7%, respectively.
The differences produced nominal p-values of 0.0012 for sustained LLDAS, 0.0002 for LLDAS-5 and 0.0253 for DORIS remission. Because these were post-hoc analyses, those values should not be interpreted as if the trial had prospectively established three additional confirmatory endpoints.
They nevertheless add an important layer to the original BICLA result. The pattern suggests that dapirolizumab’s treatment effect was not restricted to a one-time composite response at Week 48 and that a subset of patients maintained deeper disease control across multiple visits.
Why does glucocorticoid reduction matter so much in lupus drug development?
Glucocorticoids remain important for controlling active systemic lupus erythematosus, but cumulative exposure is associated with substantial long-term toxicity. Chronic treatment can contribute to osteoporosis, infection, cardiovascular and metabolic complications, cataracts and other forms of organ damage.
That creates a difficult development challenge. A new lupus therapy is more compelling if it improves disease activity while allowing clinicians to reduce corticosteroid exposure rather than simply adding another immunomodulatory drug on top of substantial glucocorticoid use.
PHOENYCS GO incorporated mandated glucocorticoid tapering for patients receiving more than 7.5 mg per day of prednisone equivalent at baseline, with tapering required to begin by Week 8 towards a target of 7.5 mg or less. The new LLDAS-5 analysis is therefore relevant because it combines disease control with a corticosteroid threshold of no more than 5 mg per day.
This still does not prove that dapirolizumab reduces long-term glucocorticoid-related organ damage. The trial lasted 48 weeks, and organ-damage outcomes generally require considerably longer observation. The ongoing open-label extension, expected to continue through 2030, may help build the longer-term safety and disease-control evidence needed to understand that question.
What does the new TRM-SLE analysis add to the dapirolizumab efficacy story?
Biogen and UCB also presented the first application of the Treatment Response Measure for Systemic Lupus Erythematosus, or TRM-SLE, to Phase 3 dapirolizumab data. TRM-SLE is a newly developed clinical outcome tool intended to assess clinically meaningful improvement across individual organ domains rather than relying on some of the more complex legacy composite instruments used in lupus trials.
In the post-hoc analysis, 61.2% of patients receiving dapirolizumab pegol achieved a clinically meaningful response in at least half of their active TRM-SLE organ domains by Week 48 compared with 43.2% receiving placebo. A response across all active measured domains was achieved by 52.5% versus 36.8%, respectively.
Most participants entered the trial with arthritis and mucocutaneous manifestations, so the analysis primarily reflects joint and skin disease rather than proving equivalent efficacy across every possible organ manifestation of lupus. Patients with certain severe manifestations also differ from the broader population encountered in clinical practice.
TRM-SLE itself remains under development and requires further validation. It was not a prespecified endpoint in PHOENYCS GO and is not currently the basis of the programme’s regulatory strategy.
Its value is therefore exploratory but potentially important. Lupus has historically been one of the more difficult diseases in which to demonstrate drug efficacy because heterogeneous manifestations and complicated composite endpoints can obscure clinically meaningful improvements. A simpler and validated multidomain tool could eventually influence how future systemic lupus trials are designed.
How does dapirolizumab pegol work, and why is its Fc-free design relevant?
Dapirolizumab pegol is a humanised, monovalent, pegylated Fab antibody fragment targeting CD40 ligand, or CD40L. Blocking CD40L signalling is intended to modulate several immune processes implicated in systemic lupus erythematosus, including B-cell activation, autoantibody production, type I interferon signalling and interactions between T cells and antigen-presenting cells.
The molecule lacks the Fc portion of a conventional monoclonal antibody. That engineering decision is important because earlier generations of antibodies targeting CD40L encountered thrombotic safety concerns associated with Fc-mediated platelet activation.
The Fc-free structure was designed to preserve CD40L inhibition while reducing that mechanism of thrombosis. PHOENYCS GO reported one thromboembolic event, a myocardial infarction, among 213 patients who received dapirolizumab pegol.
The trial does not establish that thrombotic risk has been eliminated. Lupus itself can carry elevated cardiovascular and thrombotic risk, particularly in patients with antiphospholipid antibodies, and larger exposure will be needed to characterise uncommon adverse events reliably.
That makes the confirmatory study and long-term extension important not only for efficacy but also for safety. A therapy intended for chronic use in a relatively young population needs a benefit-risk profile that remains acceptable across years rather than months.
What did PHOENYCS GO show about infections and other adverse events?
Treatment-emergent adverse events occurred in approximately 83% of patients receiving dapirolizumab pegol compared with 75% receiving placebo. Serious treatment-emergent adverse events occurred in 10% and 15%, respectively.
Serious infections occurred in about 4% of dapirolizumab-treated patients and 6% receiving placebo. Infusion-related hypersensitivity reactions occurred in approximately 3% of the active-treatment group.
One death from gangrene-related sepsis occurred in a patient receiving dapirolizumab pegol. The existence of a death or serious adverse event during a clinical trial does not by itself establish that the investigational drug caused the event, so causality should not be inferred beyond the investigators’ and sponsors’ assessments.
Discontinuations because of treatment-emergent adverse events were relatively low, at approximately 4.7% with dapirolizumab pegol and 3.7% with placebo. The overall Phase 3 safety profile therefore supported continued development, but a 321-patient study remains too small to fully define uncommon risks associated with chronic immunomodulation.
Where could dapirolizumab fit alongside Benlysta and Saphnelo?
The systemic lupus treatment landscape is no longer devoid of targeted biologics. GSK’s Benlysta, or belimumab, inhibits B-lymphocyte stimulator and is approved for active systemic lupus erythematosus and active lupus nephritis in eligible patients receiving standard therapy.
AstraZeneca’s Saphnelo, or anifrolumab, inhibits the type I interferon receptor and is approved for adults with moderate-to-severe systemic lupus erythematosus receiving standard therapy. In April 2026, the United States Food and Drug Administration also approved a subcutaneous self-administered Saphnelo formulation, adding convenience to the established intravenous option.
Dapirolizumab would enter with a different mechanism centred on the CD40-CD40L immune pathway. Mechanistic novelty alone, however, will not determine adoption. Rheumatologists will assess depth and durability of response, steroid-sparing potential, safety, route of administration, organ involvement and the strength of evidence in patients who have previously received other advanced therapies.
The intravenous every-four-week regimen may also influence positioning. If effective self-administered biologics become more prevalent in lupus, infusion-based therapy may need to demonstrate sufficient clinical differentiation to justify the additional treatment burden.
Dapirolizumab could still prove valuable for patients whose disease remains inadequately controlled despite existing options. The heterogeneity of systemic lupus means there is unlikely to be one universally optimal biologic across all manifestations and patient groups.
Why is PHOENYCS FLY now the decisive trial for Biogen and UCB?
The second confirmatory Phase 3 study is designed to enrol approximately 450 patients with moderately to severely active systemic lupus erythematosus. Like PHOENYCS GO, PHOENYCS FLY uses BICLA response at Week 48 as its primary endpoint.
The study began in November 2024 and is recruiting across more than 20 countries, with primary completion expected in 2028. UCB has indicated that topline results are also expected in 2028.
Replication matters because systemic lupus has a history of inconsistent clinical trial outcomes, partly because of disease heterogeneity, high background therapy response rates and challenges surrounding endpoint measurement. A second successful pivotal study would substantially strengthen the argument that the PHOENYCS GO result represents a reproducible therapeutic effect.
Conversely, failure to reproduce the response would make the supportive ACR analyses considerably less important. Post-hoc remission rates cannot compensate for a negative confirmatory trial.
That is why the current programme should be viewed as clinically promising but still materially de-risking rather than regulatory-ready.
What does dapirolizumab mean for Biogen and UCB strategically?
For UCB, dapirolizumab offers an opportunity to expand an immunology franchise currently driven primarily by BIMZELX into another large chronic autoimmune disease. The company is already enjoying strong investor expectations, with its Brussels-listed shares closing at €294.50 on November 10, close to their 52-week high of €301.20.
Biogen has a different strategic rationale. The company has been rebuilding its growth pipeline beyond its historic multiple-sclerosis franchise, with programmes spanning Alzheimer’s disease, rare disease, immunology and kidney disorders. Dapirolizumab provides a late-stage autoimmune asset that could become commercially important if the second Phase 3 study succeeds.
Biogen shares closed at about US$253 on November 10 after reaching a 52-week high of US$261 one day earlier. Those movements reflect the companies’ broader pipelines and financial outlooks rather than the dapirolizumab analyses alone, and no direct causal link between the ACR presentations and recent share-price performance should be assumed.
The more meaningful investor milestone remains distant but clear. PHOENYCS GO has already produced one positive, peer-reviewed Phase 3 result, while the new ACR analyses suggest that the effect extends into sustained low disease activity, remission and multidomain response.
For now, that makes dapirolizumab one of the more credible late-stage lupus programmes in development. It does not yet make it a regulatory success. PHOENYCS FLY will determine whether Biogen and UCB can convert a promising first Phase 3 result into the replicated evidence package required to challenge established lupus biologics.
